Dalia Ercan

发表

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

Aleksandra Markovets, J Carl Barrett, Geoffrey R Oxnard, 2015, Nature Medicine.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

John R. Engen, Kwok-Kin Wong, Liang Chen, 2009, Nature.

Discovery of selective irreversible inhibitors for EGFR-T790M.

Nathanael S Gray, P. Jänne, N. Gray, 2011, Bioorganic & medicinal chemistry letters.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Levi A Garraway, Kwok-Kin Wong, Neal Rosen, 2012, Cancer discovery.

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Karen Cichowski, A. Letai, R. Berkowitz, 2015, Cell.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Wei Zheng, Kwok-Kin Wong, Nathanael S Gray, 2011, Cancer research.

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.

Kwok-Kin Wong, Takeshi Shimamura, P. Jänne, 2012, Cancer research.

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

Haikuo Zhang, Gerald Lelais, Kwok-Kin Wong, 2016 .

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Doron Lipson, Hidefumi Sasaki, Roman Yelensky, 2012, Nature Medicine.

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

Taebo Sim, Takayuki Kosaka, Nathanael S. Gray, 2016, Clinical Cancer Research.